At least nine deals primarily focusing on compounds that inhibit phosphoinositide 3-kinase (PI3K) and/or its isoforms were completed over the past seven years for more than $3 billion, including milestones. Of the deals with upfront figures disclosed, the largest payment ($375 million) went to the acquisition of Calistoga Pharmaceuticals Inc. by Gilead Sciences Inc. (NASDAQ:GILD). Intellikine Inc. received the second largest up front ($190 million) from its acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Source: BCIQ: BioCentury Online Intelligence

Licensor/Acquiree

Licensee/Acquirer

Type

PI3K assets (product status at time of deal)

Financial terms

Date

Intellikine Inc.

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)

M&A

INK1117, a PI3K alpha inhibitor in Ph I for solid tumors; IPI-145, a PI3K delta/gamma inhibitor in Ph I for hematological malignancies, licensed to Infinity Pharmaceuticals Inc. (NASDAQ:INFI) in 2010; and INK128, an mTOR complex 1 (mTORC1)/ mTORC2 inhibitor in Ph I for multiple myeloma (MM) and solid tumors; plus large library of pre- clinical compounds against thePI3K/mTOR pathway and other kinases

$190M up front; up to $120M in milestones

Dec-2011 (closed Jan-2012)